GlaxoSmithKline Competitors

GlaxoSmithKline (NYSE:GSK) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Valuation and Earnings

This table compares GlaxoSmithKline and Abbott Laboratories' top-line revenue, earnings per share and valuation.

GlaxoSmithKline has higher revenue and earnings than Abbott Laboratories. GlaxoSmithKline is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

11.8% of GlaxoSmithKline shares are held by institutional investors. Comparatively, 72.6% of Abbott Laboratories shares are held by institutional investors. 10.0% of GlaxoSmithKline shares are held by insiders. Comparatively, 1.7% of Abbott Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and target prices for GlaxoSmithKline and Abbott Laboratories, as provided by MarketBeat.

Abbott Laboratories has a consensus price target of $122.0556, suggesting a potential upside of 0.19%. Given Abbott Laboratories' stronger consensus rating and higher possible upside, analysts clearly believe Abbott Laboratories is more favorable than GlaxoSmithKline.

Dividends

GlaxoSmithKline pays an annual dividend of $2.52 per share and has a dividend yield of 7.0%. Abbott Laboratories pays an annual dividend of $1.80 per share and has a dividend yield of 1.5%. GlaxoSmithKline pays out 79.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Abbott Laboratories pays out 55.6% of its earnings in the form of a dividend. GlaxoSmithKline has increased its dividend for 1 consecutive years and Abbott Laboratories has increased its dividend for 49 consecutive years.

Volatility and Risk

GlaxoSmithKline has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.

Profitability

This table compares GlaxoSmithKline and Abbott Laboratories' net margins, return on equity and return on assets.

Summary

Abbott Laboratories beats GlaxoSmithKline on 11 of the 17 factors compared between the two stocks.

Pfizer (NYSE:PFE) and GlaxoSmithKline (NYSE:GSK) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

Volatility and Risk

Pfizer has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, GlaxoSmithKline has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500.

Insider & Institutional Ownership

67.4% of Pfizer shares are owned by institutional investors. Comparatively, 11.8% of GlaxoSmithKline shares are owned by institutional investors. 0.1% of Pfizer shares are owned by insiders. Comparatively, 10.0% of GlaxoSmithKline shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Pfizer and GlaxoSmithKline's top-line revenue, earnings per share (EPS) and valuation.

Pfizer has higher revenue and earnings than GlaxoSmithKline. GlaxoSmithKline is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Pfizer and GlaxoSmithKline's net margins, return on equity and return on assets.

Dividends

Pfizer pays an annual dividend of $1.56 per share and has a dividend yield of 4.2%. GlaxoSmithKline pays an annual dividend of $2.52 per share and has a dividend yield of 7.0%. Pfizer pays out 52.9% of its earnings in the form of a dividend. GlaxoSmithKline pays out 79.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has increased its dividend for 1 consecutive years and GlaxoSmithKline has increased its dividend for 1 consecutive years.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Pfizer and GlaxoSmithKline, as reported by MarketBeat.com.

Pfizer presently has a consensus price target of $38.5714, suggesting a potential upside of 4.05%. Given Pfizer's higher probable upside, analysts plainly believe Pfizer is more favorable than GlaxoSmithKline.

Summary

Pfizer beats GlaxoSmithKline on 9 of the 15 factors compared between the two stocks.

Novartis (NYSE:NVS) and GlaxoSmithKline (NYSE:GSK) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation and dividends.

Risk and Volatility

Novartis has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500. Comparatively, GlaxoSmithKline has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500.

Profitability

This table compares Novartis and GlaxoSmithKline's net margins, return on equity and return on assets.

Dividends

Novartis pays an annual dividend of $2.08 per share and has a dividend yield of 2.4%. GlaxoSmithKline pays an annual dividend of $2.52 per share and has a dividend yield of 7.0%. Novartis pays out 39.7% of its earnings in the form of a dividend. GlaxoSmithKline pays out 79.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Novartis has raised its dividend for 1 consecutive years and GlaxoSmithKline has raised its dividend for 1 consecutive years.

Institutional & Insider Ownership

9.9% of Novartis shares are owned by institutional investors. Comparatively, 11.8% of GlaxoSmithKline shares are owned by institutional investors. 0.0% of Novartis shares are owned by company insiders. Comparatively, 10.0% of GlaxoSmithKline shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Novartis and GlaxoSmithKline, as provided by MarketBeat.com.

Novartis currently has a consensus price target of $108.50, suggesting a potential upside of 24.96%. Given Novartis' stronger consensus rating and higher probable upside, research analysts plainly believe Novartis is more favorable than GlaxoSmithKline.

Earnings & Valuation

This table compares Novartis and GlaxoSmithKline's gross revenue, earnings per share (EPS) and valuation.

Novartis has higher revenue and earnings than GlaxoSmithKline. GlaxoSmithKline is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Summary

Novartis beats GlaxoSmithKline on 9 of the 15 factors compared between the two stocks.

GlaxoSmithKline (NYSE:GSK) and Merck & Co., Inc. (NYSE:MRK) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, profitability, risk and valuation.

Insider and Institutional Ownership

11.8% of GlaxoSmithKline shares are owned by institutional investors. Comparatively, 72.9% of Merck & Co., Inc. shares are owned by institutional investors. 10.0% of GlaxoSmithKline shares are owned by insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk and Volatility

GlaxoSmithKline has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500.

Earnings and Valuation

This table compares GlaxoSmithKline and Merck & Co., Inc.'s revenue, earnings per share (EPS) and valuation.

Merck & Co., Inc. has higher revenue and earnings than GlaxoSmithKline. GlaxoSmithKline is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Dividends

GlaxoSmithKline pays an annual dividend of $2.52 per share and has a dividend yield of 7.0%. Merck & Co., Inc. pays an annual dividend of $2.60 per share and has a dividend yield of 3.4%. GlaxoSmithKline pays out 79.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Merck & Co., Inc. pays out 50.1% of its earnings in the form of a dividend. GlaxoSmithKline has raised its dividend for 1 consecutive years and Merck & Co., Inc. has raised its dividend for 1 consecutive years.

Analyst Ratings

This is a summary of current recommendations for GlaxoSmithKline and Merck & Co., Inc., as reported by MarketBeat.com.

Merck & Co., Inc. has a consensus target price of $96.2727, indicating a potential upside of 26.06%. Given Merck & Co., Inc.'s stronger consensus rating and higher possible upside, analysts clearly believe Merck & Co., Inc. is more favorable than GlaxoSmithKline.

Profitability

This table compares GlaxoSmithKline and Merck & Co., Inc.'s net margins, return on equity and return on assets.

Summary

Merck & Co., Inc. beats GlaxoSmithKline on 13 of the 16 factors compared between the two stocks.

AbbVie (NYSE:ABBV) and GlaxoSmithKline (NYSE:GSK) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, profitability, risk and dividends.

Analyst Recommendations

This is a breakdown of current ratings for AbbVie and GlaxoSmithKline, as reported by MarketBeat.

AbbVie currently has a consensus target price of $115.75, indicating a potential upside of 9.26%. Given AbbVie's stronger consensus rating and higher possible upside, equities analysts plainly believe AbbVie is more favorable than GlaxoSmithKline.

Risk & Volatility

AbbVie has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, GlaxoSmithKline has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500.

Valuation & Earnings

This table compares AbbVie and GlaxoSmithKline's top-line revenue, earnings per share (EPS) and valuation.

AbbVie has higher earnings, but lower revenue than GlaxoSmithKline. GlaxoSmithKline is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares AbbVie and GlaxoSmithKline's net margins, return on equity and return on assets.

Dividends

AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.9%. GlaxoSmithKline pays an annual dividend of $2.52 per share and has a dividend yield of 7.0%. AbbVie pays out 58.2% of its earnings in the form of a dividend. GlaxoSmithKline pays out 79.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie has raised its dividend for 49 consecutive years and GlaxoSmithKline has raised its dividend for 1 consecutive years.

Insider and Institutional Ownership

67.5% of AbbVie shares are held by institutional investors. Comparatively, 11.8% of GlaxoSmithKline shares are held by institutional investors. 0.1% of AbbVie shares are held by insiders. Comparatively, 10.0% of GlaxoSmithKline shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

AbbVie beats GlaxoSmithKline on 13 of the 17 factors compared between the two stocks.

Eli Lilly and (NYSE:LLY) and GlaxoSmithKline (NYSE:GSK) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk and profitability.

Earnings & Valuation

This table compares Eli Lilly and and GlaxoSmithKline's top-line revenue, earnings per share (EPS) and valuation.

Eli Lilly and has higher earnings, but lower revenue than GlaxoSmithKline. GlaxoSmithKline is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Eli Lilly and has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500. Comparatively, GlaxoSmithKline has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500.

Dividends

Eli Lilly and pays an annual dividend of $3.40 per share and has a dividend yield of 1.9%. GlaxoSmithKline pays an annual dividend of $2.52 per share and has a dividend yield of 7.0%. Eli Lilly and pays out 56.3% of its earnings in the form of a dividend. GlaxoSmithKline pays out 79.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Eli Lilly and has raised its dividend for 1 consecutive years and GlaxoSmithKline has raised its dividend for 1 consecutive years.

Profitability

This table compares Eli Lilly and and GlaxoSmithKline's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Eli Lilly and and GlaxoSmithKline, as provided by MarketBeat.com.

Eli Lilly and presently has a consensus target price of $196.40, indicating a potential upside of 6.80%. Given Eli Lilly and's stronger consensus rating and higher possible upside, research analysts plainly believe Eli Lilly and is more favorable than GlaxoSmithKline.

Institutional and Insider Ownership

75.6% of Eli Lilly and shares are owned by institutional investors. Comparatively, 11.8% of GlaxoSmithKline shares are owned by institutional investors. 0.1% of Eli Lilly and shares are owned by company insiders. Comparatively, 10.0% of GlaxoSmithKline shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Eli Lilly and beats GlaxoSmithKline on 12 of the 16 factors compared between the two stocks.